INTRODUCTION {#S1}
============

Traditionally in developed countries, the problem of nosocomial antimicrobial resistance has been mainly associated with a particular group of microorganisms, "the ESKAPE bugs"\[[@ref1]\]. While many bacteria remain susceptible to antimicrobial agents, this group (composed of *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa*, and *Enterobacter* species) presents a potential series of mechanisms to evade the lethal or inhibitory action of antimicrobial agents. The high antibiotic exposure due to excessive antimicrobial prescription or its inappropriate use, acquisition of resistance mechanisms either by mutational events or gene transfer and clonal spread have been the causes of their increase. Nowadays this group has been extended to other clinically relevant microorganisms and includes the overall *Enterobacterales*, *Clostridioides difficile* and all *Enterococcus* species.

In order to fight against the ESKAPE organisms, strategies such as "10 × '20" proposed by The Infectious Diseases Society of America (IDSA) were developed. The aim of this initiative was the creation of sustainable global antibacterial drug research and development enterprise with the power in the short term to develop 10 new, safe, and efficacious systemically administered antibiotics by 2020 \[[@ref2]\] especially the ESKAPE pathogens, continue to increase in frequency and cause significant morbidity and mortality. New antimicrobial agents are greatly needed to treat infections caused by Gramnegative bacilli (GNB). This was necessary due to the decrease in the number of new systemic antibacterial agents approved by the Food and Drug Administration (FDA) in the US and the European Medicines Agency (EMA) in the EU, despite the need for new antibiotic compounds. Moreover, the high rates of resistance among these microorganisms have led the World Health Organization (WHO) to recommend prioritization in the development of new antibiotics against them \[[@ref3]\].

In Spain, the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) made a study with the objective of determining the clinical impact on mortality of multi-drug resistant (MDR) infections in our country. During a one-week period (March 2018), all MDR infections were investigated in 82 hospitals. This involved a total of 903 patients infected by MDR microorganisms of whom 177 died during the first month. If this data were extrapolated to the total of hospitals in the country, this would imply a total of 35,400 annual deaths in patients presenting infections due to MDR microorganisms \[[@ref4]\].

ANTIMICROBIAL RESISTANCE IN ESKAPE ORGANISMS IN SPAIN {#S2}
=====================================================

Currently, in Spain, resistance among the ESKAPE organisms has mainly increased over the years, a fact documented in the EARS-net surveillance study \[[@ref5]\] ([figure 1](#F1){ref-type="fig"}). In *Enterococcus faecalis*, unlike *E. faecium*, a low percentage of resistance (considering the intermediate and resistant categories) to ampicillin (0.8%) and vancomycin (0.1%) whereas a 36.6% of high-level aminoglycoside resistance was observed in 2017. This is very similar to that observed in 2005. On the contrary, in *E. faecium*, ampicillin resistance has increased with respect to 2005 from 49.2% to 83.7%, the high-level aminoglycoside resistance has also experimented an increment (12.5 to 32.3%) but vancomycin resistance rates have remained low (2.4%). In *S. aureus*, methicillin resistance has slightly decreased from 29.4% to 25.3%.

![Percentage of non-susceptible ESKAPE isolates. Data obtained from the EARS-net data base (<https://ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc>, access February 2019)](revespquimioter-32-suppl-2-27-g001){#F1}

In *Acinetobacter* spp *.*, resistance to carbapenems and aminoglycosides has decreased (68.2% and 56.8%, respectively) and also, the rate of MDR isolates (51.1%) remain minor. In *P. aeruginosa*, we have more resistance than in 2005 to piperacillin-tazobactam (8.2%), ceftazidime (14.6%), carbapenems (20.7%), aminoglycosides (19.3%), fluoroquinolones (23.9%) and overall a higher percentage of MDR microorganisms (10.9%). Focusing on *Enterobacterales*, and specifically in *E. coli* and *K. pneumoniae*, the percentages of resistant isolates have increased in both species: third generation cephalosporin resistance has increased in *E. coli* (1.0% to 13.1%) and *K. pneumoniae* (7.1% to 21.7%). This trend was also observed for aminoglycosides, fluoroquinolones and carbapenems. As a consequence, the percentage of MDR *E. coli* has increased up to 5.5% and the MDR *K. pneumoniae* up to 13.0% in 2017 ([figure 1](#F1){ref-type="fig"}), the latter might also include carbapenemase producers.

CARBAPENEMASES-PRODUCING ENTEROBACTERALES {#S3}
=========================================

The problem of carbapenems resistance in *Enterobacterales* lies in a series of factors that are promoting their emergence, persistence and rapid dispersion. The increased prevalence of faecal carriage and co-colonization with carbapenemaseproducing *Enterobacterales* (CPE), the dispersion of MDR highrisk clones, the presence of co-resistance to other antimicrobials, including colistin resistance and now, the appearance of resistance determinants to new ß-lactam-ß-lactamase inhibitor combinations are the main factor driving this trend. In Europe, the EuSCAPE program performed a survey not only to determine the occurrence of carbapenemase-producing *K. pneumoniae* and *E. coli* in European hospitals but also to depict differences in the spread of different carbapenemases in different countries ([figure 2](#F2){ref-type="fig"}) \[[@ref6]\].

![Occurrence of different carbapenemases in carbapenemase-producing *Klebsiella pneumoniae* in the European survey of carbapenemase-producing *Enterobacteriaceae* (EuSCAPE) (Data obtained from reference \[[@ref6]\])](revespquimioter-32-suppl-2-27-g002){#F2}

For the same reasons, the complexity in the carbapenemase distribution in *Enterobacterales* in Spain has increased along the last years. The first detection of CPE in our country was associated with sporadic cases of metallo-ß-lactamases (MBLs) in Barcelona in 2003 \[[@ref7]\]. Later in 2007, local outbreaks in different hospitals in the Madrid area due to VIM and KPC carbapenemases were described in patients with no history of travel abroad \[[@ref8], [@ref9]\]. A national multicenter study performed in 2009 only demonstrated a very low prevalence \[[@ref10]\]. The detection of the first imported cases of NDM occurred in 2010 and the appearance of extra-hospitalary cases with no previous sanitary contact \[[@ref11]\] has continued until today with local outbreaks and dispersion in different areas of OXA-48-carrying *Enterobacterales* \[[@ref12]\]. Higher prevalence of OXA-48 was also highlighted in the EuSCAPE project with lower prevalence of KPC, VIM and NDM carbapenemases.

As mentioned before, one of the reasons of CPE dispersion is the increasing number of patients colonized with CPE. In the article of Hernández-García *et al*. \[[@ref13]\], incidence of colonization by CPE in our hospital, during a follow-up period between March 2014 and March 2016, was 2% (161/8,209) of patients, and of these 0.9% were colonized at admission and 1.1% acquired colonization during admission. The principal colonizer was *K. pneumoniae* (54%) followed by *E. coli* (19%) mainly as OXA-48 (64.1%) and VIM-1 (26.8%) producers. Also, 20% of patients were colonized with two or three different CPE (co-colonization).

Other factors fueling emergence and dispersion of CPE is the presence of carbapenemases in the so-called MDR highrisk clones. A recent study performed in Spain analyzing the population structure of CPE revealed that carbapenemases concentrate in a few clones when compared with the susceptible population. These MDR high-risk clones are the cause of multiple outbreaks throughout our country as the one described in Cordoba \[[@ref14]\]. This originated in a patient transferred from an Italian hospital, and there was a range of 67 infected and 14 colonized patients and a mortality of 30% due to a *K. pneumoniae*-ST512-KPC-3 resistant to third generation cephalosporins, carbapenems, tobramycin, amikacin, fluoroquinolones and colistin. Also, there is a significant percentage of CPE isolates from clinical samples in ICU admitted patients. This was demonstrated in a recent multicenter study performed in Spain in 8 hospitals, with 23.1% of ESBL-producing *Klebsiella* spp. and 20% of carbapenemase-producing *Klebsiella* spp. \[[@ref15]\]. These isolates also showed high co-resistances to non-β-lactam antimicrobials.

EMERGENCE OF CEFTAZIDIME-AVIBACTAM RESISTANCE {#S4}
=============================================

Nowadays, we have new compounds available designed to fight against CPE as new ß-lactam-ß-lactamase inhibitors combinations such as ceftazidime-avibactam and meropenemvarbobactamin and in the future imipenem-relebactam. The first one, already available in the US and EU, is a combination of ceftazidime, a classical third generation cephalosporin, and avibactam, a non-ß-lactam (diazabicyclooctane) ß-lactamase inhibitor, that is active against Ambler class A and C ß-lactamases and possesses activity against some Ambler class D enzymes, including OXA-48 producers.

Despite its short life in the clinical setting, isolates with acquired resistance to this combination has already been occasionally described. The mechanisms involved in this resistance include: a) Overexpression of extended-spectrum AmpC in *E. cloacae* and mutations in AmpC from *P. aeruginosa*; b) Increased hydrolytic activity of *bla*~CTX-M-14~ variants; c) KPC-*K. pneumoniae* with multiple resistance mechanisms such as KPC-3 overexpression plus porin deficiency (*ompK35/ompK36*) and SHV-12 with enhanced efflux activity (*AcrAB*); and d) double or triple *bla*~KPC-3~ mutations and *bla*~KPC-2~ mutations that confer resistance to ceftazidime-avibactam. Interestingly these last resistance mechanisms might produce a reversion of carbapenem susceptibility, a phenomenon that has been named as "collateral sensitivity".

Many of these resistance mutations appear after ceftazidime-avibactam treatment, such as *bla*~KPC~ mutations and lead to treatment failure and resistance development \[[@ref16]\]. This had been reproduced with in vitro studies subjecting the strains of KPC producing *K. pneumoniae* to various concentrations of antibiotic and counting the number of colonies that grew \[[@ref17]\]. Furthermore, in these strains with *bla*~KPC~ gene mutation, at the same time as the development of ceftazidime-avibactam resistance, there was restoration of meropenem susceptibility occurred during or after ceftazidime-avibactam treatment \[[@ref18]\].

In our hospital, we have detected a rapid dissemination of a KPC-3-producing *K. pneumoniae* ST307 clone. In a year period, we detected 353 patients with carbapenemase-producing *K. pneumoniae* isolates of whom 19.2% (68/353) were KpST307-KPC-3 producers. In two patients, ceftazidime-avibactam resistance developed associated with ceftazidime-avibactam treatment due to the emergence of a KPC-3 variant \[[@ref19]\].

CONCLUSIONS {#S5}
===========

In summary, there has been an increase of ESKAPE organisms in Spain during the last years. In addition, CPE have been dispersed throughout all the country with a dominance of OXA-48 producing *K. pneumoniae* isolates but with an increasing prevalence of KPC producers and maintenance of VIM producers. This complexity in the carbapenemase-distribution among *Enterobacterales* is also due to high faecal carriers co-colonized with different CPE, the dispersion of MDR highrisk clones, and the co-resistance with non-ß-lactam antimicrobials, including colistin. Moreover, the emergence of resistance to new β-lactamβ-lactamase inhibitor combinations with restoration of carbapenem susceptibility due to new KPC mutations has also been detected in Spain.
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